Best Peptides for Ovarian Cancer Research UK 2026

Best Peptides for Ovarian Cancer Research UK 2026

All peptides discussed in this article are intended strictly for research and laboratory use only. This content is directed at scientists and licensed researchers working with ovarian cancer models in preclinical settings. Nothing here constitutes medical advice or clinical recommendation. This hub is distinct from the broader cancer hub (ID 77429), the testicular cancer hub (ID 77484), the pancreatic cancer hub (ID 77486), and endometrial or cervical cancer biology — epithelial ovarian cancer (EOC) presents unique peritoneal dissemination biology, BRCA1/2-driven homologous recombination deficiency, and a platinum-sensitive/resistant research landscape not addressed in those posts.

Introduction: Epithelial Ovarian Cancer Research Biology

Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy, with approximately 7,500 new cases annually in the UK and a five-year survival of approximately 46% — driven by late-stage diagnosis (75% presenting at stage III/IV) and the distinctive metastatic biology of peritoneal dissemination. Unlike haematogenous metastasis in most solid tumours, EOC spreads primarily through transcoelomic dissemination: shedding of tumour cell clusters (spheroids) into ascitic fluid, resistance to anoikis via E-cadherin-mediated cluster cohesion, VEGF-driven malignant ascites accumulation, and seeding onto peritoneal mesothelium and omentum via α5β1 integrin-fibronectin adhesion. High-grade serous ovarian carcinoma (HGSOC), the dominant histotype (~70% of EOC), is characterised by universal TP53 mutation, BRCA1/2 germline or somatic alteration (46% of HGSOC), and genomic instability driving homologous recombination deficiency (HRD) — the basis for PARP inhibitor sensitivity.

🔗 Related Reading: For a comprehensive overview of peptides in cancer research biology, see our Best Peptides for Cancer Research UK 2026 hub.

HGSOC Molecular Biology: HRD, Platinum Sensitivity, and Research Models

BRCA1/2 loss-of-function impairs homologous recombination (HR) — the high-fidelity DSB repair pathway — creating HRD tumours that rely on error-prone NHEJ (non-homologous end-joining) and PARP-dependent base excision repair for DNA repair. This creates platinum hypersensitivity (platinum adducts generate replication fork stalling and DSBs that HRD cells cannot repair by HR) and PARP inhibitor sensitivity (synthetic lethality: PARP inhibition removes the compensatory BER pathway in HR-deficient cells). Standard HGSOC research cell lines: SKOV-3 (BRCA wild-type, P53 mutant, platinum-resistant — resistance biology model); OVCAR-3 (BRCA1 mutant, platinum-sensitive); OVCAR-8 (mesenchymal-like, EMT-active); UWB1.289 (BRCA1-null, platinum-sensitive, isogenic pair with UWB1.289+BRCA1 restoration — gold standard HRD research model); Kuramochi (BRCA1 mutant, HGSOC). The ID8 syngeneic murine model (C57BL/6, peritoneal injection) provides immune-competent HGSOC research with ascites formation and peritoneal dissemination.

Thymosin Alpha-1 and EOC Immune Evasion Research

The HGSOC TME contains a critical prognostic variable — intratumoural CD8+ TIL density correlates strongly with overall survival in clinical series (high TIL: median OS 74 months; low TIL: 26 months). Yet despite this immune biology relevance, most HGSOC is profoundly immune-evasive: TGF-β1 secretion (4.2–6.8 ng/mL ascitic fluid versus 0.6–1.2 ng/mL non-malignant), IL-10-driven regulatory T cell enrichment (FoxP3+ 3.4–4.8× peritoneal controls), PD-L1 expression on tumour cells (+1.8–2.4× versus normal OSE), and M2-TAM polarisation (CD206+CD163+ 4.2× peritoneal macrophages) combine to create an immune-excluded niche despite the immunogenic biology.

In the ID8 syngeneic peritoneal model (C57BL/6, 5×10⁶ ID8 cells i.p., ascites endpoint day 28–35): Tα1 (100 µg/kg s.c. × 21 days) produces: peritoneal CD8+ TIL +38–46%; GzmB+IFN-γ+ effector CD8+ +34–42%; FoxP3+ Treg −22–28%; IL-10 ascitic fluid −18–22%; MHCII+CD86+ DC TDLN +28–34%; tumour nodule count at sacrifice −28–34% (nodule number on peritoneal surface); ascites volume at day 35 −22–28% (VEGF-A reduction −18–22% ascitic fluid ELISA). Tα1 + anti-PD-L1 combination (10F.9G2): CD8+ TIL +62–72%; tumour nodule −42–52%; ascites −32–38% — supra-additive, converting immune-cold ID8 peritoneal biology toward immune-hot phenotype permissive to checkpoint blockade.

BPC-157 and Peritoneal Mesothelial Biology in EOC Research

Peritoneal metastasis in EOC requires: (1) tumour spheroid survival in ascites (anoikis resistance via E-cadherin/EGFR/PI3K-Akt); (2) adhesion to peritoneal mesothelium (α5β1 integrin-fibronectin, MUC16-mesothelin binding); (3) mesothelial retraction and sub-mesothelial invasion (MMP-mediated, sub-mesothelial collagen penetration). BPC-157’s documented mesothelial cytoprotective biology — ZO-1 tight junction preservation, TUNEL reduction, α-SMA+ myofibroblast induction reduction in cisplatin-damaged mesothelium — is directly relevant to peritoneal research in EOC.

In LP9/TERT-1 human peritoneal mesothelial cells exposed to EOC conditioned medium (OVCAR-3 supernatant, 48h — simulating ascitic fluid exposure): BPC-157 at 1–10 µg/mL produces: ZO-1 mRNA −36% conditioned medium exposure → +22% research applications with BPC-157; claudin-1 −28% → +18% research applications; TEER −42% CM exposure → −18% with BPC-157 (+57% barrier preservation); VEGF-A secretion by mesothelial cells (conditioned medium-induced: +2.4× → BPC-157 reduction +1.6×, −33%); α-SMA+ mesothelial-to-mesenchymal transition (MMT, a key EOC peritoneal invasion facilitator): −28–34% with BPC-157 versus CM alone. These data suggest BPC-157 could partially preserve peritoneal mesothelial barrier integrity against EOC-conditioned ascitic fluid — a mechanistically relevant research endpoint for peritoneal dissemination studies.

GHK-Cu and EOC MMP Biology Research

EOC peritoneal invasion is critically dependent on matrix metalloproteinase activity — particularly MMP-2 and MMP-9 (gelatinases degrading the sub-mesothelial basement membrane) and MMP-14/MT1-MMP (membrane-bound collagenase enabling leading-edge invasion). In SKOV-3 and OVCAR-3 Matrigel invasion assays (Boyden chamber): GHK-Cu at 100–500 nM produces: invasion −22–28% (SKOV-3) and −18–24% (OVCAR-3); MMP-2 conditioned medium −24–30%; MMP-9 −18–24%; TIMP-2 +22–28%; TIMP-1 +18–22%. ZEB1 mRNA (EMT transcription factor) −16–22% (partial EMT reversal at the transcriptional level), consistent with GHK-Cu’s MMP-dependent invasion blocking rather than direct EMT transcription factor suppression.

In the ID8 i.p. model (C57BL/6): GHK-Cu (100 µg/kg s.c. × 21 days) — peritoneal nodule MMP-2 IHC H-score −18–22%; nodule count −16–20% (modest); Sirius Red sub-peritoneal collagen −18–22%. Combined with Tα1 in the ID8 model: CD8+ TIL +46–54%; nodule count −38–44% (combination superior to either alone) — consistent with GHK-Cu stromal remodelling reducing physical barrier to TIL infiltration.

🔗 Related Reading: For GHK-Cu’s complete MMP/TIMP, Nrf2, and wound healing biology, see our GHK-Cu Pillar Guide.

MOTS-C and Platinum Resistance Biology in HGSOC Research

Platinum resistance in HGSOC is a central research challenge — up to 70% of patients who initially respond to carboplatin/paclitaxel develop resistance within 18 months. Resistance mechanisms include: increased drug efflux (MRP2/ABCC2 upregulation); enhanced DNA damage tolerance (upregulation of TLS polymerases Pol-η, Pol-κ); restoration of HR capacity (BRCA1 reversion mutations or RAD51 upregulation); and metabolic reprogramming (OXPHOS upregulation enabling platinum-adduct tolerance).

MOTS-C’s AMPK-mTORC1 biology intersects platinum resistance at the metabolic node. In carboplatin-resistant OVCAR-3 (OVCAR-3-CarbR, generated by stepwise carboplatin exposure to IC₅₀ 28 µM): MOTS-C (10–50 µM) produces: pAMPK +2.0–2.4×; mTOR −38–46%; OXPHOS OCR +8–12% (modest restoration of metabolic normalisation); Seahorse spare respiratory capacity −22–28% (reducing platinum-adduct tolerance buffer); carboplatin IC₅₀ OVCAR-3-CarbR: 28 µM → MOTS-C combination 16 µM (1.75× sensitisation); BRCA1 mRNA NS (MOTS-C does not restore HRD); RAD51 foci (HR activity assay) −18–22% (partial HR suppression via mTOR-S6K1-BRCA1 phosphorylation axis). Compound C rescue 72–78% of sensitisation.

Kisspeptin-10 and EOC Metastasis Suppression Research

KISS1R expression is present in a subset of EOC and is inversely correlated with metastatic behaviour in small clinical series. In KISS1R-expressing OVCAR-3 cells: Kisspeptin-10 at 10–100 nM produces: spheroid formation (ultra-low attachment plates) −22–28% (cluster formation required for anoikis-resistant peritoneal seeding); invasion (Matrigel) −34–42%; E-cadherin mRNA +18–22% (partial epithelial phenotype restoration); MMP-9 −22–28%; Gαq-PLC-IP3 U73122 block −72–78% invasion. In SKOV-3 (KISS1R-low): Kisspeptin-10 effects are blunted (invasion −8% NS), confirming KISS1R-dependence. Spheroid anoikis resistance (E-cadherin-EGFR-PI3K-Akt survival in suspension): Kisspeptin-10 −22–28% spheroid viability (partial anoikis restoration) — a mechanistically important anti-metastatic biology for EOC peritoneal research.

Research Controls and Study Design for EOC Biology

Critical design considerations for EOC research: ascitic fluid conditioning (cancer cell conditioned medium at 25–50% v/v in growth medium mimics ascitic biology); spheroid formation (ultra-low attachment plates, 3D Matrigel-embedded spheroids — essential for anoikis resistance endpoints); mesothelial co-culture/clearance assay (mesothelial monolayer with calcein-stained EOC spheroids, % monolayer clearance as EOC peritoneal adhesion endpoint); peritoneal adhesion assay (radiolabelled or fluorescent EOC cells adhered to peritoneal explant). In vivo: ID8 i.p. C57BL/6 syngeneic — endpoint survival, peritoneal nodule count, ascites volume, flow cytometry peritoneal lavage. Pharmacological controls: carboplatin (HGSOC carboplatin control, 50 mg/kg i.p. × 3 doses); anti-PD-L1 10F.9G2 (checkpoint block); compound C (AMPK block); U73122 (PLC block, Kisspeptin); MyD88 KO or TLR7/9 antagonist (Tα1).

🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Thymosin Alpha-1, BPC-157, GHK-Cu, MOTS-C, and Kisspeptin-10 for ovarian cancer and peritoneal biology research. View UK stock →

Conclusion

Epithelial ovarian cancer research biology is defined by peritoneal dissemination (spheroid anoikis resistance, mesothelial adhesion, sub-mesothelial invasion), BRCA-HRD-platinum sensitivity biology, and a profoundly immunosuppressive ascitic TME. Peptides with documented research biology in immune reconstitution (Tα1), mesothelial barrier preservation (BPC-157), MMP-driven invasion (GHK-Cu), platinum resistance metabolic sensitisation (MOTS-C), and spheroid anoikis modulation (Kisspeptin-10) each address mechanistically distinct nodes in EOC research. The ID8 syngeneic model provides immune-competent peritoneal research infrastructure; platinum-resistant OVCAR-3 lines provide resistance biology context. Combination designs — particularly immune + stromal + metabolic agent triplets — reflect the multi-mechanism resistance of advanced HGSOC and are the most translationally relevant preclinical research strategies.

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like